Zacks Investment Research downgraded shares of Natera, Inc. (NASDAQ:NTRA) from a hold rating to a sell rating in a report published on Wednesday morning.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

A number of other research analysts have also commented on NTRA. Cowen and Company lowered their price objective on shares of Natera from $17.00 to $14.00 and set an outperform rating on the stock in a research note on Tuesday, March 14th. Canaccord Genuity raised their price objective on shares of Natera from $14.00 to $16.00 and gave the company a buy rating in a research note on Wednesday, May 10th. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $16.20.

Shares of Natera (NASDAQ:NTRA) opened at 10.86 on Wednesday. The company has a 50 day moving average price of $10.57 and a 200-day moving average price of $9.86. Natera has a 12-month low of $7.35 and a 12-month high of $13.40. The firm’s market cap is $574.30 million.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, May 9th. The medical research company reported ($0.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.09. Natera had a negative net margin of 60.89% and a negative return on equity of 101.63%. The company had revenue of $46.90 million for the quarter, compared to analyst estimates of $42.82 million. During the same quarter in the prior year, the business earned ($0.17) EPS. Natera’s revenue was down 24.2% compared to the same quarter last year. Analysts expect that Natera will post ($1.97) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Natera, Inc. (NASDAQ:NTRA) Stock Rating Lowered by Zacks Investment Research” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/07/17/natera-inc-nasdaqntra-stock-rating-lowered-by-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP bought a new position in Natera during the fourth quarter worth approximately $121,000. Russell Investments Group Ltd. bought a new position in Natera during the fourth quarter worth approximately $130,000. American International Group Inc. raised its position in Natera by 7.1% in the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock worth $142,000 after buying an additional 1,068 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Natera by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock worth $143,000 after buying an additional 194 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Natera by 45.3% in the first quarter. Goldman Sachs Group Inc. now owns 17,386 shares of the medical research company’s stock worth $154,000 after buying an additional 5,417 shares in the last quarter. Institutional investors and hedge funds own 59.56% of the company’s stock.

Natera Company Profile

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.